|Assessment Status||Assessment process complete|
|Indication||Treatment of adult patients with CD30+ Hodgkin’s lymphoma at increased risk of relapse or progression following autologous stem cell transplant.|
|Rapid review commissioned||30/12/2019|
|Rapid review completed||29/01/2020|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brentuximab vedotin compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||05/02/2020|
|Pre-submission consultation with Applicant||19/05/2020|
|Full submission received from Applicant||11/01/2021|
|Preliminary review sent to Applicant||12/07/2021|
|NCPE assessment re-commenced||06/08/2021|
|Factual accuracy sent to applicant||24/09/2021|
|NCPE assessment re-commenced||30/09/2021|
|NCPE assessment completed||22/10/2021|
|NCPE assessment outcome||The NCPE recommends that brentuximab vedotin be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*|
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medicinal Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations, December 2022.